InvestorsHub Logo
Followers 44
Posts 10453
Boards Moderated 0
Alias Born 01/13/2016

Re: surf1944 post# 699

Saturday, 05/06/2023 9:58:49 PM

Saturday, May 06, 2023 9:58:49 PM

Post# of 4148
Guess you missed this..

The Company believes the safety and efficacy results from its FORTRESS Phase 2b FM study support progression of IMC-1 to Phase 3 development for “new” patients, who represent the vast majority of the FM patient community.

Analysis of the Company’s recent FORTRESS Phase 2b FM study data revealed:

“New” FM patients treated with its novel FM development candidate, IMC-1 , who were recruited into FORTRESS via advertising, demonstrated statistically significant reductions in FM related pain, fatigue, anxiety and depressive symptoms and showed an overall improvement in their global health status.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VIRI News